Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome vs Chidamide in R/R PTCL
NCT04668690Phase 3Active, not recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in peripheral T-cell lymphoma (PTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Apr 2021; status: active, not recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04668690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668690.